Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares Outstanding
Ratios

Solid Biosciences (SLDB) Shares Issued (2018 - 2026)

Quarterly results put Shares Issued at $18000.0 for Q1 2026, changed N/A from a year ago — trailing twelve months through Mar 2026 was $24000.0 (down 99.72% YoY), and the annual figure for FY2025 was $6000.0, down 98.69%.

Solid Biosciences has reported Shares Issued over the past 8 years, most recently at $18000.0 for Q1 2026.

  • Shares Issued reached $18000.0 in Q1 2026 per SLDB's latest filing, up from $6000.0 in the prior quarter.
  • Across five years, Shares Issued topped out at $72.5 million in Q4 2022 and bottomed at $6000.0 in Q2 2025.
  • Median Shares Issued over the past 5 years was $151000.0 (2024), compared with a mean of $9.3 million.
  • Peak annual rise in Shares Issued hit 153.79% in 2022, while the deepest fall reached 99.98% in 2022.
  • Over 5 years, Shares Issued stood at $72.5 million in 2022, then tumbled by 96.5% to $2.5 million in 2023, then plummeted by 99.25% to $19000.0 in 2024, then crashed by 68.42% to $6000.0 in 2025, then soared by 200.0% to $18000.0 in 2026.
  • Business Quant data shows Shares Issued for SLDB at $18000.0 in Q1 2026, $6000.0 in Q2 2025, and $19000.0 in Q4 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Shares Issued (Qtr)
1 Quantum Biopharma 1,384,976.65 Bn 1,384,976.64 Bn - 5.40 Mn
2 Alterity Therapeutics 777,208.84 Bn 777,208.81 Bn - -
3 Legend Biotech 2,801.00 Bn 2,800.10 Bn 242.10 Mn -
4 Nanobiotix 2,226.01 Bn 2,225.95 Bn - -
5 Akari Therapeutics 605.66 Bn 605.66 Bn - -
6 Vertex Pharmaceuticals 110.17 Bn 102.92 Bn 2.59 Bn 27.00 Mn
7 Regeneron Pharmaceuticals 66.86 Bn 58.11 Bn 3.31 Bn 163.10 Mn
8 Evaxion A 65.12 Bn 65.10 Bn - -
9 Alnylam Pharmaceuticals 39.94 Bn 36.94 Bn 959.66 Mn 13.16 Mn
10 Solid Biosciences 713.77 Mn 333.09 Mn - 18,000.00

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 18,000.00
Mar 31, 2026 18,000.00
Jun 30, 2025 6,000.00
Jun 30, 2025 6,000.00
Dec 31, 2024 19,000.00
Dec 31, 2024 19,000.00
Sep 30, 2024 3.10 Mn
Sep 30, 2024 3.10 Mn
Jun 30, 2024 5.40 Mn
Jun 30, 2024 5.40 Mn
Mar 31, 2024 151,000.00
Mar 31, 2024 151,000.00
Jun 30, 2023 2.54 Mn
Jun 30, 2023 2.54 Mn
Dec 31, 2022 72.53 Mn
Dec 31, 2022 72.53 Mn
Mar 31, 2022 22,000.00
Mar 31, 2022 22,000.00
Dec 31, 2021 -134.84 Mn
Dec 31, 2021 -134.84 Mn
Mar 31, 2021 134.88 Mn
Mar 31, 2021 134.88 Mn
Dec 31, 2019 38.67 Mn
Dec 31, 2019 38.67 Mn
Mar 31, 2018 133.69 Mn
Mar 31, 2018 133.69 Mn